CoreWeave Faces Challenges as AI Infrastructure Play Stumbles
CoreWeave Inc.’s rapid rise seems to be losing momentum as challenges arise in the artificial intelligence infrastructure landscape, raising concerns among investors.
The stock, which counts Nvidia Corp. as a backer, has experienced a significant drop—down 17% in under a month. This fall contrasts sharply with its initial public offering in March, where valuations had ballooned. Furthermore, an upcoming series of share lockups set to expire next month could add pressure, enabling early investors to cash out. Adding to the turbulence, a $9 billion plan to acquire Core Scientific Inc. has led at least three analysts to downgrade their assessments of CoreWeave, resulting in mixed reactions to the stock’s performance. During early trading on Thursday, CoreWeave shares slipped by 1%.
“We’ve been pretty lenient with CoreWeave, especially since it’s not making money and won’t for some time,” noted Mark Malek, chief investment officer at Siebert Financial. “The lockup doesn’t alter the fundamentals, but it might give some pause if you’re considering buying now.”
The stock has become one of the more contentious investments on Wall Street, skyrocketing from below $20 billion post-IPO to nearly $100 billion by June. Traders are particularly drawn to CoreWeave for its cloud computing services aimed at large operators like Microsoft Corp., banking on the ongoing AI funding surge.
However, profitability isn’t expected until late 2026, making it a target for short sellers and investors focused on value who seem to be cautious about its soaring valuations. Even after this recent downturn, CoreWeave trades at about nine times its projected sales over the next year, compared to roughly five times for the Nasdaq 100.
CoreWeave hasn’t provided any comments to requests from Bloomberg News. One factor contributing to the rapid rise was the limited number of shares available for trading. Currently, only about 13% of CoreWeave’s shares—around 47 million—are actively traded, a figure that will rise significantly in August when roughly 290 million more shares become available.
While some analysts suggest that the influx of new shares could worsen the current selling pressure, others on Wall Street remain optimistic about their expected earnings for the second quarter. CoreWeave is anticipating a net loss of $236 million for this period.
“I think CoreWeave will perform much better than it’s showing right now,” asserted Mark Klein, CEO of Suro Capital. “Traditional metrics matter, but we also need to recognize the value that leading brands command.”
Still, skepticism lingers across Wall Street. Data from Bloomberg indicates that only three out of 22 analysts covering the stock advocate for a buy. The average price target suggests a potential upside of over 30%, though that does not compensate for the lackluster outlook, which ranks among the poorest in Bloomberg’s major capital stock index.
This week, trading Core Scientific shares drew negative attention from analysts. Three firms, including Needham, Mizuho, and Stifel, downgraded their ratings after the announcement of the Core Scientific acquisition. Both Needham and Mizuho cited concerns about the rating shift, while Stifel acknowledged the long-term potential but highlighted issues related to impending dilutions and lockup expiration dates.
“We see significant potential, yet all I’m observing right now is an increasing loss,” remarked Marek from Siebert. “I prefer to leave money on the table rather than waste it. For now, all I can do is smile, watch the market rally, and think it’s fascinating.”
